Literature DB >> 20716384

Potential use of RNA interference in cancer therapy.

Connor Phalon1, Donald D Rao, John Nemunaitis.   

Abstract

RNA interference (RNAi) is an evolutionary conserved mechanism for specific gene silencing. This mechanism has great potential for use in targeted cancer therapy. Understanding the RNAi mechanism has led to the development of several novel RNAi-based therapeutic approaches currently in the early phases of clinical trials. It remains difficult to effectively deliver the nucleic acids required in vivo to initiate RNAi, and intense effort is under way in developing effective and targeted systemic delivery systems for RNAi. Description of in vivo delivery systems is not the focus of this review. In this review, we cover the rationale for pursuing personalised cancer therapy with RNAi, briefly review the mechanism of each major RNAi therapeutic technique, summarise and sample recent results with animal models applying RNAi for cancer, and provide an update on current clinical trials with RNAi-based therapeutic agents for cancer therapy. RNAi-based cancer therapy is still in its infancy, and there are numerous obstacles and issues that need to be resolved before its application in personalised therapy focusing on patient-cancer-specific targets can become standard cancer treatment, either alone or in combination with other treatments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716384     DOI: 10.1017/S1462399410001584

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  14 in total

1.  Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion.

Authors:  Zhaoming Li; Tian Tian; Xiaopeng Hu; Xudong Zhang; Lifeng Li; Feifei Nan; Yu Chang; Xinhua Wang; Zhenchang Sun; Feng Lv; Mingzhi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

2.  Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.

Authors:  Tatsuaki Tagami; Amr S Abu Lila; Mariko Matsunaga; Naoto Moriyoshi; Hiroyuki Nakamura; Kazuya Nakamura; Takuya Suzuki; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

3.  N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery.

Authors:  Gang Liu; Jin Xie; Fan Zhang; Zhiyong Wang; Kui Luo; Lei Zhu; Qimeng Quan; Gang Niu; Seulki Lee; Hua Ai; Xiaoyuan Chen
Journal:  Small       Date:  2011-08-22       Impact factor: 13.281

Review 4.  Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery.

Authors:  Joel C Sunshine; Corey J Bishop; Jordan J Green
Journal:  Ther Deliv       Date:  2011-04

5.  Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.

Authors:  Maria C Palanca-Wessels; Anthony J Convertine; Richelle Cutler-Strom; Garrett C Booth; Fan Lee; Geoffrey Y Berguig; Patrick S Stayton; Oliver W Press
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

Review 6.  SIRT3 and cancer: tumor promoter or suppressor?

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Biochim Biophys Acta       Date:  2011-05-07

7.  RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice.

Authors:  Jibin Yao; Mingxu Da; Tiankang Guo; Yaoxing Duan; Yongbin Zhang
Journal:  Tumour Biol       Date:  2013-03-10

Review 8.  Pancreatic cancer actionable genes in precision medicine and personalized surgery.

Authors:  Juehua Yu; Shi-He Liu; Robbi Sanchez; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Surgeon       Date:  2016-06-28       Impact factor: 2.392

Review 9.  PDX1 associated therapy in translational medicine.

Authors:  Juehua Yu; Shi-He Liu; Robbi Sanchez; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Ann Transl Med       Date:  2016-06

10.  Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene.

Authors:  J E Hanning; H K Saini; M J Murray; S van Dongen; M P A Davis; E M Barker; D M Ward; C G Scarpini; A J Enright; M R Pett; N Coleman
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.